Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Mitchell, Aaron P ^a   Simpson, Ross J ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Drug cost; Primary prevention; Statin; Systematic review

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DRUG COST; DYSLIPIDEMIA; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG COSTS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRIMARY PREVENTION; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84866428493     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-373     Document Type: Article

References (22)

1. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. LaRosa JC, He J, Vupputuri S, JAMA 1999 282 24 2340 2346 10.1001/jama.282.24.2340 10612322
2. Statin prescription in men and women at cardiovascular risk: to whom and when? Brugts JJ, Deckers JW, Curr Opin Cardiol 2010 25 5 484 489 20625281
3. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Brugts JJ, Yetgin T, Hoeks SE, et al. BMJ 2009 338 2376 10.1136/bmj.b2376 19567909
4. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Amarenco P, Labreuche J, Lancet Neurol 2009 8 5 453 463 10.1016/S1474-4422(09)70058-4 19375663
5. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Ray KK, Seshasai SRK, Erqou S, et al. Arch Intern Med 2010 170 12 1024 1031 10.1001/archinternmed.2010.182 20585067
6. Drug treatment of lipid disorders. Knopp RH, N Engl J Med 1999 341 7 498 511 10.1056/NEJM199908123410707 10441607
7. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Mihaylova B, Briggs A, Armitage J, et al. Lancet 2005 365 9473 1779 1785 15910950
8. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. Shepherd J, Cobbe SM, Ford I, et al. N Engl J Med 1995 333 20 1301 1307 10.1056/NEJM199511163332001 7566020
9. Cost effectiveness of statins in coronary heart disease. Franco OH, Peeters A, Looman CWN, Bonneux L, J Epidemiol Community Health 2005 59 11 927 933 10.1136/jech.2005.034900 16234419
10. A systematic review and economic evaluation of statins for the prevention of coronary events. Ward S, Lloyd Jones M, Pandor A, et al. Health Technol Assess 2007 11 14 1 160 iii-iv 17927921
11. Determinants of the cost-effectiveness of statins. Morrison A, Glassberg H, J Manag Care Pharm 2003 9 6 544 551 14664662
12. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Ann Intern Med 2009 150 4 243 254 19221376
13. Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines. Caro J, Huybrechts KF, Klittich WS, Jackson JD, McGuire A, Am J Manag Care 2003 9 7 477 489 12866627
14. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Prosser LA, Stinnett AA, Goldman PA, et al. Ann Intern Med 2000 132 10 769 779 10819699
15. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Pignone M, Earnshaw S, Tice JA, Pletcher MJ, Ann Intern Med 2006 144 5 326 336 16520473
16. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Evans C, Tavakoli M, Crawford B, Health Care Manag Sci 2004 7 1 43 49 14977093
17. Tough questions about the value of statin therapy for primary prevention: did JUPITER miss the moon? Curtiss FR, Fairman KA, J Manag Care Pharm 2010 16 6 417 423 20635832
18. Findlay S, The statin drugs: prescription and price trends, October 2005 to December 2006 Consumers Union, 2007 Available at: www.consumerreports.org/ health/resources/pdf/best-buy-drugs/Statins-RxTrend-FINAL-Feb2007.pdf
19. Prediction of coronary heart disease using risk factor categories. Wilson PW, DAgostino RB, Levy D, et al. Circulation 1998 97 18 1837 1847 10.1161/01.CIR.97.18.1837 9603539
20. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Grover SA, Ho V, Lavoie F, et al. Arch Intern Med 2003 163 3 333 339 10.1001/archinte.163.3.333 12578514
21. Statins for the primary prevention of cardiovascular disease. Taylor F, Ward K, Moore TH, et al. Cochrane Database Syst Rev 2011 1 D004816 21249663
22. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. Greving JP, Visseren FLJ, de Wit GA, Algra A, BMJ 2011 342 1672 10.1136/bmj.d1672 21450800